These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12180646)

  • 1. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
    Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
    Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats.
    Gao W; Kageyama M; Inoue Y; Tadano J; Fukumoto K; Fukushima K; Yamasaki D; Nishimura A; Yoshikawa Y; Shibata N; Takada K
    Biol Pharm Bull; 2003 Feb; 26(2):199-204. PubMed ID: 12576680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
    Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
    J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice.
    Lenhard JM; Croom DK; Weiel JE; Spaltenstein A; Reynolds DJ; Furfine ES
    J Nutr; 2000 Sep; 130(9):2361-6. PubMed ID: 10958836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
    Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
    J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals.
    Morse GD; Rosenkranz S; Para MF; Segal Y; Difrancesco R; Adams E; Brizz B; Yarasheski KE; Reichman RC
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3373-81. PubMed ID: 16048950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.
    Chi J; Jayewardene AL; Stone JA; Motoya T; Aweeka FT
    J Pharm Biomed Anal; 2002 Oct; 30(3):675-84. PubMed ID: 12367693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.
    Riddler SA; Havlir D; Squires KE; Kerr B; Lewis RH; Yeh K; Wynne LH; Zhong L; Peng Y; Deutsch P; Saah A
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3877-82. PubMed ID: 12435691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
    Sadler BM; Gillotin C; Lou Y; Eron JJ; Lang W; Haubrich R; Stein DS
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3663-8. PubMed ID: 11709366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir.
    Chaillou S; Durant J; Garraffo R; Georgenthum E; Roptin C; Clevenbergh P; Dunais B; Mondain V; Roger PM; Dellamonica P
    HIV Clin Trials; 2002; 3(6):493-501. PubMed ID: 12501133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.
    Pfister M; Labbé L; Hammer SM; Mellors J; Bennett KK; Rosenkranz S; Sheiner LB;
    Antimicrob Agents Chemother; 2003 Jan; 47(1):130-7. PubMed ID: 12499180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
    Pfister M; Labbé L; Lu JF; Hammer SM; Mellors J; Bennett KK; Rosenkranz S; Sheiner LB;
    Clin Pharmacol Ther; 2002 Aug; 72(2):133-41. PubMed ID: 12189360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
    Kuschak D; Mauss S; Schmutz G; Gantke B
    Clin Lab; 2001; 47(9-10):471-7. PubMed ID: 11596909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model.
    Shibata N; Gao W; Okamoto H; Kishida T; Iwasaki K; Yoshikawa Y; Takada K
    J Pharm Sci; 2002 Mar; 91(3):680-9. PubMed ID: 11920753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.
    Chai H; Yang H; Yan S; Li M; Lin PH; Lumsden AB; Yao Q; Chen C
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):12-9. PubMed ID: 16123675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
    AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.
    Hoetelmans RM; Reijers MH; Weverling GJ; ten Kate RW; Wit FW; Mulder JW; Weigel HM; Frissen PH; Roos M; Jurriaans S; Schuitemaker H; de Wolf F; Beijnen JH; Lange JM
    AIDS; 1998 Jul; 12(11):F111-5. PubMed ID: 9708400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats.
    Shibata N; Kageyama M; Kishida T; Kimura K; Yoshikawa Y; Kuwahara T; Toh J; Shirasaka T; Takada K
    Biopharm Drug Dispos; 2003 Nov; 24(8):335-44. PubMed ID: 14595702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
    Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.
    Seminari E; Guffanti M; Villani P; Gianotti N; Cusato M; Fusetti G; Galli A; Castagna A; Regazzi M; Lazzarin A
    Eur J Clin Pharmacol; 2005 Aug; 61(7):545-9. PubMed ID: 16041598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.